Pharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
About This Group of Stocks
Our Expert Thinking
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major shift in pharmaceutical strategy. Large corporations are increasingly looking to external innovation to strengthen their drug pipelines, particularly in the high-growth mental health sector where demand and investment are rising rapidly.
What You Need to Know
This group focuses on biotech companies developing innovative therapies for psychiatric and neurological conditions. These specialised firms often represent cutting-edge research and could benefit from increased M&A activity as major pharmaceutical players compete for novel drug candidates in mental health.
Why These Stocks
These publicly traded biotechs were handpicked for their promising assets in mental health treatments. As heightened M&A interest drives competition among major pharma companies, these firms represent the types of innovative companies that could attract acquisition attention and potentially see valuations rise.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+465.40%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 465.4% over the next year.
Stocks Rated Buy by Analysts
12 of 13 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
M&A Target Potential
With AbbVie's billion-dollar move setting the tone, these biotech firms developing mental health therapies could become prime acquisition targets for major pharmaceutical companies seeking innovation.
Mental Health Market Boom
The mental health sector is experiencing unprecedented growth and investment, creating opportunities for companies with promising psychiatric and neurological treatments to capture significant market value.
Cutting-Edge Innovation
These companies represent the forefront of mental health research, developing novel therapies that could revolutionise treatment for conditions with massive unmet medical needs.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Uncle Sam's Semiconductor Stake
The U.S. government is considering an equity stake in Intel to boost domestic semiconductor manufacturing. This strategic move could create a ripple effect, benefiting other American companies involved in the chip-making industry.
The Cybersecurity Consolidation Wave
Accenture's record-breaking acquisition of CyberCX signals a major consolidation trend in the cybersecurity sector. This move highlights the growing demand for AI-powered security solutions, creating potential opportunities for other specialized cybersecurity firms to benefit from increased investment and M&A activity.
American Chipmakers: A Tariff-Driven Shift
President Trump has threatened to impose tariffs of up to 300% on semiconductors to boost domestic production. This creates a potential investment opportunity in U.S.-based semiconductor companies that stand to gain from a shift toward onshore manufacturing.
Frequently Asked Questions
Everything you need to know about the product and billing.